Survey shows little effect of aspirin in reducing breast cancer risk
Other research has shown that it can also protect consumers from the danger of developing colorectal cancer.
The consumption of aspirin a day can so little to protect a woman’s risk of developing one of the most common types of breast cancer, said a study released by the journal Breast Cancer Research.
The research, conducted by scientists at the National Cancer Institute confirms previous studies that the painkiller could reduce the risk of estrogen receptor-positive cancer, which constitutes about 60 percent of breast cancers.
Aspirin is an anti-inflammatory painkiller to relieve symptoms of arthritis and its anticoagulant nature helps prevent heart attacks and other cardiovascular problems.
Other research has shown that it can also protect consumers from colorectal cancer risk.
The study, conducted in about 127,000 women, indicated that daily aspirin reduced the risk of such cancer by 16 percent, said Gretchen Gierach of the National Cancer Institute, part of the National Institutes of Health an agency of the U.S. Government
The women were between 51 and 72 years and had no cancer at the start of the study, about 18 percent consumed an aspirin a day and seven years after it was determined that 4,500 had developed breast cancer, the study said.





